Antibody Genome Protein Reagent 
Drug Discovery World
MAY 25, 2023
The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos. Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.
The Pharma Data
JANUARY 24, 2021
Dr. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing. As part of his work with Juno and Kite, Dr. Bond led R&D collaborations with genome editing companies including Editas Medicine and Sangamo Therapeutics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 12, 2022
Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.
Drug Discovery World
JULY 18, 2023
Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.
Drug Discovery World
JUNE 6, 2023
I think they are still just at the cusp of really understanding how we use the molecular degrader and how we optimise them towards something that is clinically relevant, rather than a research tool which shows we can degrade the protein and understand the pharmacology but isn’t necessarily endowed with all the right properties to be a drug.
Drug Discovery World
FEBRUARY 8, 2023
This helps ensure a high concentration of loaded capsids and adequate removal of impurities, such as host cell proteins and DNA. The threat of empty capsids Capsids are the protein shell that would usually enclose the genetic material of a virus. A crucial part of the AAV workflow is the purification of viral vectors.
The Pharma Data
OCTOBER 14, 2020
VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity.
Expert insights. Personalized for you.
52 
Let's personalize your content